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1. Introduction 
As part of our interest in the synthesis of dehydro- 
peptides [2], we reported the preparation of a highly 
potent [D-Ala 2, APhe 4, MetS]-enkephalin amide [ 1 ], 
which had 5-times the activity of the corresponding 
saturated enkephalin in the stimulated guinea pig 
ileum assay and the mouse tail-flick test [3]. In gen- 
eral, the dehydroamino acid residue might enhance 
activity by virtue of an increased receptor-binding 
affinity, by its ability to react irreversibly [4] with a 
nucleophile on the receptor surface or by increasing 
resistance to enzymic degradation. A peptide messen- 
ger (hormone) most probably contains 'binding' and 
'active' elements in its amino acid sequence [5]. The 
placement of a double bond into an amino acid resi- 
due in the 'binding' element could increase binding 
and elicit a stronger bio-response. 
We have synthesized a series of unsaturated enke- 
phalin analogs, dehydro-enkephalins (AEK), which 
contain AAla 2 or 3 APhe 4 or ALeu s residues (fig.l). 
Attempts to prepare ATyrl-enkephalins have failed 
because of the hydrolytic instability of an N-terminal 
ATyr residue. This paper discusses the binding affinity 
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Fig.1. The structures of unsaturated (a) and saturated (b) 
amino acid residues. 
and selectivity of these AEKs for 2 types of opiate 
receptors [6], and shows that incorporation ofa dehy- 
droamino acid residue is an effective way to obtain 
enkephalin analogs with full receptor activity which 
are resistant o enzymic hydrolysis without changing 
the selectivity. 
2. Materials and methods 
2.1. Peptide synthesis 
The peptides were synthesized by classical methods, 
and the dehydroamino acid moieties were prepared as 
in [7 9] and were confirmed by 1N-NMR and UV 
difference spectroscopy [10]. All APhe and ALeu 
peptides had the z~configuration [ 11 ]. Free AEKs 
were liberated by HF-anisole and purified by gel fil- 
tration (Bio-Gel P-2, aq. AcOH) followed by partition 
chromatography (Sephadex G-I 0, n -BuOH-AcOH-  
HEO (4:1:5)). Homogeneity was determined by thin- 
layer chromatography, paper electrophoresis and 
amino acid analysis (before and after hydrogenation 
of the unsaturated moieties). 
2.2. Receptor binding assays 
Binding assays using [3H] [D-AIa 2, D-LeuS]-enke - 
phalin ([3H]DADLE, 40 Ci/mmol) and [3H]dihydro- 
morphine ([3H] DHM, 47.5 Ci/mmol) were performed 
as in [12]. Potencies expressed in EDso have been 
estimated utilizing an RIA computer program as in [13]. 
3. Results and discussion 
Paper 2 in the series Dehydro-enkephalins; paper 1 is [ 1 ] 
+ Present address: NIH, NICHD, Bethesda, MD 20205, USA 
The substitutions of D-Ala 2 by AAla 2 (I), L-Phe 4 
by APhe 4 (Il l) and L-Leu s by ALeu s (IV) preserve 
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Table 1 
Binding activity of [ D-Ala*]dehydroenkephalins 
- 
AEK [aH]DADLE [‘H]DHM ED,,, vs [3H]DHM 
EDsoa (?2 SEM)b %ActC ED,, (?2 SEM) %Act. ,?D,, vs [ 3H] DADLE 
- 
[ AAla*, Leu5] (I) 2.8 (2.2-3.5) 68 6.1 (6.4-6.9) 125 2.2 
[D-Ala’, AAla3, Leu’] (IL) 4.5 (3.5 -5.7) 42 26 (21-32) 29 5.8 
[D-Ala*, APhe4, Leu’] (ILL) 1.9 (1.5-2.4) 100 6.4 (5.7-7.9) 119 3.4 
[D-Ala’, ALeuS] (IV) 2.5 (1.9-3.2) 76 8.7 (6.9-10.1) 87 3.5 
[AAla’]-desLeu5-OMe (V) 180 (142-228) 1 76 (61-94) 10 0.4 
[D-Ala’, D-Leu’] (ST,) 1.9 (1.5-2.4) 100 1.6 (6.1-9.4) 100 4.0 
[ LetIS] (ST,) 2.4 (1.8-3.0) 79 15 (12-19) 51 6.2 
a-Endorphin 2.3 (1.8-2.9) 83 2.8 (2.2-3.5) 270 1.2 
a nM in the presence of bacitracin (100 fig/ml) 
b Means and standard deviations from 3 or 4 independent assays were calculated assuming a log distribution of 
the variance [ 131, from the log value of the IS’D,,. The standard error of the mean (SEM) is based on a pooled 
estimate of the standard deviation. and hence on a higher value of degree of freedom 
c Relative potency (%) against ST, 
almost full receptor activity (80- 120%) as shown in 
table 1. These replacements result in a loss of chirality 
but a gain in rigidity and hydrophobicity. Since 
D-Phe4-enkephalins have no binding activity [ 141, 
position 4 apparently influences the conformation 
required for receptor binding. These results indicate 
that the APhe4 moiety in III maintains this stereo- 
chemical requirement and sustains full binding activity 
(table 1). On the other hand, the considerable activity 
of [D-Ala’, ALeus]-enkephalin (IV) is presumably 
due to the insensitivity of the opiate receptors to 
chirality in position 5, because both L- and D-Leu’- 
enkephalins are fully active [ 141. 
Unlike APhe and ALeu, AAla, which has no sub- 
stituents on P-carbon, must be the most electrophilic 
dehydroamino acid and, consequently, most reactive 
toward nucleophiles [2]. However, in these receptor 
binding assays, [AAla’, Leu’]-enkephalin (I) showed 
almost the same affinities as the saturated analog 
(ST,) and the APhe4 and ALeus analogs. Replace- 
ment of Gly3 by different amino acids drastically 
reduces the opiate activities [ 141. Surprisingly, 
[D-Ala’, AAla3, Leu’]-enkephalin (II) maintains most 
of its activity both in t3H] DADLE (42%) and in 
[ 3H] DHM binding (29%). 
These results suggest hat ‘dehydro-enkephalins’ 
sustain a normal receptor interaction because the 
incorporation of dehydroamino acids confers the 
necessary structural elements: rigidity, hydrophobicity 
and conformation on the molecule. This change does 
not, however, produce the large enhancement ofbind- 
270 
ing affinity which would be expected if covalent 
bond formation with the receptor surface were part 
of the binding mechanism. 
The influence of a dchydroamino acid moiety on 
the selectivity of peptides for the two classes of opiate 
receptors [6] has beenexamined by using [3H]DADLE 
for peptide receptors (6) and [3H] DHM for opiate 
receptors (p) as tracers. The ratio of potencies in 
these two assays, f?“Dse using [3H]DHM/ED50 using 
[3H]DADLE suggests preferences for one of the two 
types of receptors (table 1). fi-Endorphin has almost 
7r 
Gly2 D-Ala2 AAla AAlaZ-desLe& 
Fig.2. Potency ratio (ED,, w [‘H]DHM/ED,, vs [3H]- 
DADLE) for different substituents in position 2 of enkephalin: 
ratio = 1, equipotent; ratio >1, more potent for 6 receptors; 
ratio <1, more potent for n receptors. 
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the same affinity for both receptors, while enkepha- 
lins generally have a greater affinity for '6' receptors. 
Our AAlaZ-tetrapeptide (V), which has weak activity, 
shows a higher selectivity for '~' receptors. This result 
is mainly due to the removal of the C-terminal resi- 
due [ 15]. As shown in fig.2, D-Ala2-enkephalin prefers 
'/l' receptors as compared with GlyLenkephalin 
(STs), and the replacement of D-Ala s by AAla 2 facili- 
tates the shift of selectivity towards '/l' receptors. 
These results indicate that an increase in hydropho- 
bicity at position 2 causes a preference for the '/l' 
receptors. 
In contrast, APhe4-(III) and ALeuS-(IV) enkephalins 
have a preference for '6'  sites as do the parent satu- 
rated analog (ST1). Increased hydrophobicity in posi- 
tions 4 and 5 does not facilitate selective interactions 
with the receptors. It appears that the increase of 
hydrophobicity by ag-dehydrogenation s most pro- 
nounced in case of AAla, and miniinized in the more 
sterically congested APhe and ALeu compounds. 
The enzymatic degradation of enkephalins occurs 
most rapidly at Tyr l -G ly  s in rat brain homogenates 
[16] and in plasma [17]; and also at Glya-Phe 4 by a 
dipeptidyl carboxypeptidase, enkephalinase [18]. 
Substitution of D-Ala s for Gly s gives a peptide with 
good agonist properties having a longer duration of 
action [16]. The chemical modifications ( ubstitu- 
tions by D-amino acids, N-CH3, amides and esters) of 
enkephalin, which provide resistance to these enzymic 
degradations, however, usually are associated with a 
loss of '8' vs '~' receptor selectivity [ 19]. Dehydro- 
peptides have been shown to be resistant to enzymic 
hydrolysis [1,20,21 ]. Since analogs III and IV show 
the full receptor activity without changing selectivity, 
it appears that aS-dehydrogenation, r incorporation 
o fa  dehydroamino acid, is an effective way to produce 
enkephalins resistant to enzymatic degradation with 
an unaltered full receptor affinity. To elucidate other 
effects of  dehydroamino acid moieties additional bio- 
logical assays are in progress. 
Acknowledgements 
References 
[1] Paper, I., English, M. L. and Stammer, C. H. (1978) 
Biochem. Biophys. Res. Commun. 85,780-782. 
[2] Stammer, C. H. (1981) in: Chemistry and Biochemistry 
of Amino Acids, Peptides and Proteins (Weinstein, B. 
ed) vol. 6, in press. 
[3] Chipkin, R. E., Stewart, J. M. and Stammer, C. H. 
(1979) Biochem. Biophys. Res. Commun. 87,890-895. 
[4] Breitholle, E. G. and Stammer, C. H. (1976) J. Org. 
Chem. 41, 1344-1349. 
[5] Walter, R. (1977) Fed. Proc. FASEB 36, 1872-1878. 
[6] Lord, J. A. H., Walerfield, A. A., Hughes, J. and 
Kosterlitz, H. W. (1977) Nature 267,495-499. 
[7] Photaki, I. (1963) J. Am. Chem. Soc. 85, 1123-1126. 
[8] Bergmann, M., Schmidt, U. and Miekeley, A. (1930) Z. 
Physiol. Chem. 187,264-276. 
[9] Poisel, H. and Schmidt, U. (1976) Angew. Chem. Int. 
Ed. Engl. 15,294-295. 
[ 10] Shimohigashi, Y., Dunning, J. W. jr, Grim, M. D. and 
Stammer, C. H. (1981) J. Chem. Soc. Perkin Trans 2, 
in press. 
[ 11 ] Srinivasan, A. and Olsen, R. (1976) Tetrahedron Lett. 
891-894. 
[12] Pert, C. B. and Snyder, S. H. (1974) Mol. Pharmacol. 
10,868-879. 
[ 13 ] Fader, V. B. and Rodbard, D. (1975 ) Radioimmunoassay 
Data Processing, 3rd ed, vol. 1, Natl. Tech. Infor. Set. 
Report no. PB246223. 
[ 14] BeddeU, C. R., Clark, R. B., Follenfant, R. L., Lowe, 
L. A., Ubatuba, F. B. and Miller, R. J. (1977) in: Bio- 
logical Activity and Chemical Structure (Buisman, 
J. A. K. ed) pp. 177-193, Elsevier/North-Holland, 
Amsterdam, New York. 
[15] Ronai, A. Z., Szekely, J. I., Berzetei, I., Miglecz, E. and 
Bajusz, S. (1979) Biochem. Biophys. Res. Commun. 91, 
1239-1249. 
[16] Pert, C. B., Pert, A., Chang, J. and Fong, B. (1976) 
Science 194,330-332. 
[ 17] Hambrook, J. M., Morgan, B. A., Rance, M. J. and 
Smith, C. F. C. (1976) Nature 262, 782-783. 
[18] Malfroy, B., Swerts, J. P., Guyon, A., Roques, B. P. 
and Schwartz, J. C. (1978) Nature 276,523-526. 
[19] Chang, K.-J. and Cuatrecasas, P. (1979) J. Biol. Chem. 
254, 2610-2618. 
[20] English, M. L. and Stammer, C. H. (1978) Biochem. 
Biophys. Res. Commun. 83, 1464-1467. 
[21] Grim, M. D., Chauhan, V., Shimohigashi, Y., Kolar, 
A. J. and Stammer, C. H. (1981) J. Org. Chem. 46, 
2671-2673. 
We wish to thank Drs J. Travis and M. Morii, Uni- 
versity of Georgia, for their amino acid analyses of 
our peptides. We are grateful to the National Institute 
for Drug Abuse for the financial support of grant 
DA02938. 
271 
